Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Other

F. Hoffmann-la Roche Ag

Syntex LLC

Todd Richard Elworthy

David Bernard Smith

Michael Garret Roepel

David John Morgans, Jr

Eric Brian Sjogren

Ronald Charles Hawley

Peter H Nelson

Robert James Weikert

John W Patterson

David Garrett Loughhead

Alicia Cervantes

Dean R Artis

Teresa Lara

Fidencio Franco

Ann M Waltos

Alejandra Trejo

Francisco X Talamas

Mario Fernandez

Yan Lou

Timothy D Owens

Rama K Kondru

Robert Than Hendricks

Zachary Kevin Sweeney

James Patrick Dunn

Michael Soth

Dimitrios Stefanidis

Johannes Cornelius Hermann

Hanbiao Yang

Daisy Joe DuBois

Mario Fern Andez

Francisco X Talam As

Jurg R Pfister

John C Rohloff

Joan Heather Hogg

Michael G Roepel

Remy Lemoine

Joe Timothy Bamberg

Mark Smith

Keith Adrian Walker

Counde O'Yang

Francisco Javier Lopez-Tapia

Alam Jahangir

Hans Maag

David Bruce Repke

Calvin Wesley Yee

Angel Guzman

Saul Jaime-Figueroa

Daisy Joe Du Bois

Helen Y Wu

Joshua Kennedy-Smith

Jaehyeon Park

David E Clarke

Jeffrey Wu

Tara Mirzadegan

Fancisco X Talamas

Eric Brian Sjorgren

Gary W Bantle

Sunil Sahdeo

Arturo Perez-Medrano

Mark Bartlett

The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R, R, R, R, R, are as defined herein. 

Heterocyclic antiviral compounds

The application discloses compounds of Formula I: wherein Q, Q, R, R, R, and n are defined as described herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.

Salicylamide derivatives as nicotinic alpha 7 modulators

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q and R are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Compounds of the formula: wherein R, R, Ar, Ar, and n are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.

Tetrazole-substituted aryl amide derivatives and uses thereof

Compounds of formula I, wherein R, R, R, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. 

Non-nucleoside reverse transcriptase inhibitors

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficiency virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficiency virus containing a compound according to formula I where R, R, R, R, R, are as defined herein. 

The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficieny virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficieny virus containing a compound according to formula I where R, R, R, R, R, R, Rand Rare as defined herein 

The invention provides compounds of the Formula: wherein m, n, A, X, Y, Z, R, R, R, R, R, R, Rand Rare as defined herein, and pharmaceutically acceptable salts, solvates, prodrugs, single isomers or racemic or non-racemic mixture of isomers thereof. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

2-Piperidone derivatives as prostaglandin agonists

This invention relates to compounds which are generally EPreceptor agonists and which are represented by Formula I:wherein A is a &#x2014;CH&#x2014;CH&#x2014;, or &#x2014;CH&#x2550;CH&#x2014;; B is absent, an aryl, or heteroaryl group; Ris alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclylalkyl, aryl, arylalkyl or heteroaryl, when B is aryl or heteroaryl and R, R, Rand Rare not simultaneously hydrogen, or Ris heterocyclylalkyl, aryl, or heteroaryl when B is absent and R, R, Rand Rare simultaneously hydrogen; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

8-aza-11-deoxy prostaglandin analogues

This invention relates to 8-aza prostanoid analogs which are generally EPreceptor agonists and are represented by Formula I:wherein Q, B, X, J, Z, A and R-Rare as defined, their synthesis and use for treatment of osteoporosis and increasing bone density.

2-pyrrolidone derivatives as prostanoid agonists

Compounds of Formula I: ##STR1## where R.sup.5 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## and the pharmaceutically acceptable salts and N-oxides thereof, are .alpha..sub.1 -adrenergic receptor antagonists useful for the treatment of diseases involving directly or indirectly an obstruction of the lower urinary tract, such as benign prostatic hyperplasia.

Pyrimidinedione, pyrimidinetrione, triazinedione and

The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1;

�3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,

Growing community of inventors

Los Altos, CA, United States of America

Todd Richard Elworthy